Drug Profile
Research programme: chronic lymphocytic leukaemia biomarkers - KineMed
Latest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator KineMed
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for research development in Chronic-lymphocytic-leukaemia(Diagnosis) in USA
- 18 Nov 2014 Early research in Chronic lymphocytic leukaemia (Diagnosis) in USA (unspecified route)